| |
|
|
|
|
|
|
|
Respiratory drug
discovery, current developments and future challenges
Thursday 14th June
2012
Novartis, GB- Horsham, West Sussex RH12 5AB |
Chronic respiratory diseases such as asthma, chronic obstructive pulmonary
disease (COPD), allergic rhinitis and cystic fibrosis remain a considerable
healthcare burden with significant unmet medical need. Acute lower
respiratory tract infections are the leading cause of death among all
infectious diseases. Asthma and COPD in particular are becoming more common
and thus the demand for continued advancements in respiratory drug discovery
has grown significantly in recent years. It is estimated that the commercial
respiratory pharmaceutical market will grow to $31 billion by 2014. A
previous SMR meeting in 2007 included the current thinking, at the time, in
the area of airway drug delivery and the challenges and developments in the
classic drugs for respiratory diseases which form the mainstay of inhaled
treatments including beta-2 agonists, glucocorticoids and muscarinic
antagonists.
This symposium brings together international experts from the pharmaceutical
industry to review the latest therapeutic developments and to discuss the
challenges in both the discovery and clinical development of novel
therapeutics for lung diseases. Topics include the translational medicine
development challenges for novel respiratory therapies, assessing the
pharmacokinetics and local toxicity of inhaled therapies, strategies to
enhance duration of action in the lung and novel approaches to treat
respiratory tract infections. This symposium will also feature a selection
of case histories for both small molecule and biological approaches.
|
|
|
|
What would you like to do? |
|
|
|
|
|
|
|
|
